title: Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women.
abstract: The impact of a 3-month continuous administration of transdermal estradiol (E2-TTS 50; 50 micrograms/day) or oral conjugated estrogen (CE; 0.625 mg/day) on glucose and lipid metabolism was investigated in two groups (n = 15/group) of postmenopausal women. Fasting levels of glucose, insulin, and C-peptide; C-peptide/insulin ratio (index of hepatic insulin clearance); and their responses to a 75-g oral glucose tolerance test (OGTT) were evaluated before and after 3 months of continuous estrogen administration. E2-TTS 50 modified carbohydrate metabolism, decreasing fasting insulin levels (P less than 0.01) and increasing the pancreatic islet response to glucose challenges, as indicated by an increased integrated value of the C-peptide curve associated with OGTT (P less than 0.05). Despite greater C-peptide secretion, integrated peripheral insulin after OGTT was decreased (P less than 0.05). The resulting increase in the integrated curve of the molar C-peptide/insulin ratio (P less than 0.01) indicated elevated hepatic insulin clearance after E2-TTS 50 administration. CE treatment did not modify carbohydrate metabolism, except for reducing fasting glucose levels (P less than 0.01). Neither therapy modified lipid metabolism, but a slight increase in circulating triglycerides (P less than 0.01) was observed during CE administration. Our data show that the addition of low doses of natural estrogens does not negatively influence glucose and lipid metabolism in postmenopausal women. By contrast, reversal of postmenopausal hypoestrogenism to early follicular phase estrogenic values with E2-TTS 50 administration seems to exert a beneficial effect on glucose metabolism by increasing hepatic insulin clearance.
authors.affiliation: Department of Reproductive Medicine, University of California-San Diego, La Jolla 92093-0802.
authors.forename: A
authors.initials: A
authors.lastname: Cagnacci
authors.forename: R
authors.initials: R
authors.lastname: Soldani
authors.forename: P L
authors.initials: PL
authors.lastname: Carriero
authors.forename: A M
authors.initials: AM
authors.lastname: Paoletti
authors.forename: P
authors.initials: P
authors.lastname: Fioretti
authors.forename: G B
authors.initials: GB
authors.lastname: Melis
mesh_terms: D000279:Administration, Cutaneous; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D007700:Kinetics; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D008076:Cholesterol, HDL; D004966:Estrogens, Conjugated (USP); D007328:Insulin; D014280:Triglycerides; D004958:Estradiol; D002784:Cholesterol